Substantia Nigra Neurons In Corticobasal Degeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Corticobasal degeneration (CBD) is a rare progressive neurodegenerative disorder characterized by asymmetric cortical dysfunction and extrapyramidal signs. The substantia nigra (SN) is consistently affected, with dopaminergic neuron loss contributing to the parkinsonian features observed in CBD patients.
- Astrocytic Plaques: Characteristic astrocytic lesions in CBD
- Coiled Bodies: Oligodendroglial tau inclusions
- Neuronal Tau: Thread-like inclusions in neurons
- 4R Tau: Predominance of 4-repeat tau isoforms
- SNc Dopaminergic Neurons: 30-50% reduction in pigmented neurons
- Parkinsonian Correlation: Severity correlates with rigidity and bradykinesia
- Asymmetry: Often more pronounced on the clinically affected side
- Denervation: Moderate to severe dopaminergic denervation
- Motor Symptoms: Contributes to bradykinesia and rigidity
- Levodopa Response: Typically poor to moderate
- Tyrosine Hydroxylase: Reduced TH expression in surviving neurons
- Dopamine Transporter: Decreased DAT binding on SPECT/PET
- Vesicular Monoamine Transporter: VMAT2 deficiency
- Hyperphosphorylation: Abnormal tau accumulation
- Microtubule Destabilization: Impaired axonal transport
- Axonal Degeneration: Distal axonopathy preceding cell death
- Complex I Deficiency: Impaired oxidative phosphorylation
- Oxidative Stress: Increased ROS production
- Energy Failure: ATP depletion in vulnerable neurons
- Bradykinesia: Slowness of movement
- Rigidity: Often asymmetric
- Dystonia: Limb dystonia common
- Myoclonus: Cortical myoclonus characteristic
- Apraxia: Ideomotor apraxia most common
- Alien Limb Phenomenon: Involuntary limb movements
- Cortical Sensory Loss: Astereognosis, agraphesthesia
| Feature |
CBD |
PD |
| Symmetry |
Asymmetric |
Typically symmetric |
| Tremor |
Less common |
Classic resting tremor |
| Levodopa response |
Poor |
Good initially |
| Cortical signs |
Present |
Absent |
| Progression |
Rapid |
Slow |
- Levodopa: Limited benefit
- Dopamine Agonists: Modest improvement sometimes
- Anticholinergics: For dystonia
- Tau aggregation inhibitors
- Neuroprotective strategies
- Cell replacement therapy
The study of Substantia Nigra Neurons In Corticobasal Degeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. PMID:23359374
- Dickson DW, et al. Neuropathology of corticobasal degeneration: specificity of the cortical-type tauopathy. J Neuropathol Exp Neurol. 2010;69(12):1198-1207. PMID:21107038
- Ling H, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. J Neurol Neurosurg Psychiatry. 2010;81(12):1273-1280. PMID:20543555
- Boxer AL, et al. Advances in progressive supranuclear palsy and corticobasal degeneration. Nat Rev Neurol. 2014;10(8):435-446. PMID:25038808
- Stamelou M, et al. Corticobasal syndrome: diagnostic and therapeutic challenges. Lancet Neurol. 2012;11(10):918-928. PMID:22995694
- Kouri N, et al. Corticobasal degeneration: pathology and molecular mechanisms. Acta Neuropathol. 2011;121(5):589-605. PMID:21369744
- Revesz T, et al. Neuropathology of tauopathies. Brain Pathol. 2015;25(5):621-634. PMID:26369680
- Josephs KA, et al. Neuropathologic and imaging correlates of the corticobasal syndrome. Neurology. 2014;83(14):1266-1273. PMID:25150284